$ cat ./records/worlds-first-malaria-vaccine-pilot-programme-launches-in-malawi-g-2019.txt
World's first malaria vaccine pilot programme launches in Malawi, Ghana, and Kenya using Gates-funded Mosquirix
[RECORD.TXT] · cat --full
The world's first pilot deployment of a malaria vaccine — RTS,S/Mosquirix, funded through over $200 million in Gates Foundation grants — launched in Malawi on April 23, 2019, followed by Ghana on April 30 and Kenya on September 13. The three-country WHO-managed pilot targeted children under two years old and began generating real-world efficacy, safety, and implementation data that would inform the WHO's landmark full recommendation two years later in October 2021. Within its first years, the pilot delivered over 1 million doses across the three countries.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation renewed grant to Grantmakers Concerned with Immigrants and Refugees for US immigrant advocacy coordination
Next →
Breakthrough Energy Ventures Invests in Pivot Bio — Nitrogen-Fixing Microbial Coating to Replace Synthetic Fertiliser
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.